SCHEMBL24982409

SCHEMBL24982409

Nc1ncnn2c([C@H]3O[C@H](CO)[C@@H](O)[C@H]3O)ccc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HIF1A Q16665 2/20 0.46
▸ POLRMT O00411 1/20 0.42
▸ GAPDH P04406 3/20 0.41
▸ DOT1L Q8TEK3 2/20 0.41
▸ ADORA3 P0DMS8 2/20 0.41
▸ SLC28A2 O43868 2/20 0.41
▸ DPP4 P27487 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ SLC28A1 O00337 1/20 0.41
▸ MAP3K7 O43318 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ ADORA2A P29274 1/20 0.41
▸ ADORA2B P29275 1/20 0.41
▸ ADORA1 P30542 1/20 0.41
▸ STAT6 P42226 1/20 0.41
▸ PI4KA P42356 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ PI4K2B Q8TCG2 1/20 0.41
▸ SLC29A1 Q99808 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25008855 1.00 HIF1A (0.46) HIF1APOLRMTGAPDHDOT1LADORA3
SCHEMBL16710417 1.00 HIF1A (0.46) HIF1APOLRMTGAPDHDOT1LADORA3
SCHEMBL19101808 1.00 HIF1A (0.46) HIF1APOLRMTGAPDHDOT1LADORA3
SCHEMBL24982322 1.00 HIF1A (0.46) HIF1APOLRMTGAPDHDOT1LADORA3
SCHEMBL10154369 1.00 HIF1A (0.46) HIF1APOLRMTGAPDHDOT1LADORA3
SCHEMBL22381795 0.90 POLRMT (0.41) HIF1APOLRMTGAPDHDOT1LADORA3
SCHEMBL16479516 0.89 POLRMT (0.40) HIF1APOLRMTGAPDHDOT1LADORA3
SCHEMBL881562 0.89 POLRMT (0.40) HIF1APOLRMTGAPDHDOT1LADORA3
SCHEMBL806951 0.89 POLRMT (0.40) HIF1APOLRMTGAPDHDOT1LADORA3
SCHEMBL19101901 0.89 POLRMT (0.40) HIF1APOLRMTGAPDHDOT1LADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115610-A1 PROCESS FOR THE CATALYTIC GLYCOSYLATION OF ARENES STUDIENGESELLSCHAFT KOHLE GGMBH (DE) 2025-04-10 — — US disclosed
CN-111542531-B Substituted nucleosides, nucleotides and analogues thereof 詹森生物制药有限公司 2024-07-19 — — CN disclosed
EP-4130001-A1 PROCESS FOR THE DIRECT CATALYTIC GLYCOSYLATION OF ARENES Studiengesellschaft Kohle mbH (DE) 2023-02-08 — — EP disclosed
CN-114641485-A Compounds and methods for treating COVID-19 辉瑞大药厂 2022-06-17 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250115610-A1 PROCESS FOR THE CATALYTIC GLYCOSYLATION OF ARENES GALE, UGT1A4, CYP3A4 HIF1A 2023/4885POLRMT 982/4885GAPDH 439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback